Allogeneic Cell Articles & Analysis
7 articles found
In hematological malignancies, complete response rates to CAR-T cells can exceed 80%. These responses are often durable in nature and have attracted considerable excitement and investment in the development of cell therapies for an expanded range of indications, particularly in solid tumors. ...
In addition, gut flora may be a new strategy to improve the prognosis of allogeneic hematopoietic cell transplantation in the future. There does not appear to be a common mechanism for how bacteria and drugs interact. ...
MPS I is caused by deficiency of the lysosomal enzyme a-L-iduronidase (IDUA) leading to GAG accumulation in multiple tissues and organs This accumulation results in a complex array of progressive, multi-systemic pathologies, including CNS manifestations Approved therapies include enzyme replacement therapy (ERT), with chaperone and gene therapies under investigation Treatment with approved ...
HYPOTHESIS: sustained therapeutic effect could be achieved by administration of IDUA-secreting allogeneic human cells shielded within spheres designed to avoid immune rejection and pericapsular fibrotic overgrowth ...
Chimeric antigen receptor T-cells (CAR-T) are one of the first clinically approved therapies to take full advantage of the most significant advancements in immunology and genetic engineering. The resulting therapeutics have been shown to produce remission rates exceeding 80% in patients with CD19+ B-cell lymphoma, making them nothing short of remarkable [1]. Unfortunately, CAR-T cells seem ...
We are developing an injectable disc cell therapy (IDCT) that has the potential to disrupt the way chronic back pain is treated. IDCT is an allogeneic, non-surgical cell therapy, meaning it’s an injectable treatment that is produced from donor tissue (as opposed to the patient’s own) and available off-the-shelf. Because IDCT is ...
Abstract Natural killer (NK) cells hold promise for improving the therapeutic potential of allogeneic hematopoietic transplantation, but their effectiveness is limited by inhibitory HLA types. ...